Published in J Oncol on March 10, 2010
Preeclampsia up-regulates angiogenesis-associated microRNA (i.e., miR-17, -20a, and -20b) that target ephrin-B2 and EPHB4 in human placenta. J Clin Endocrinol Metab (2012) 1.15
Molecular mechanisms of tumor angiogenesis. Genes Cancer (2011) 0.96
Human placental microRNAs and preeclampsia. Biol Reprod (2013) 0.94
Irradiation affects cellular properties and Eph receptor expression in human melanoma cells. Cell Adh Migr (2012) 0.93
EphA2 receptor activation by monomeric Ephrin-A1 on supported membranes. Biophys J (2011) 0.92
Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor. ChemMedChem (2012) 0.86
TWEAK/Fn14 pathway is a novel mediator of retinal neovascularization. Invest Ophthalmol Vis Sci (2014) 0.86
Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies. World J Clin Oncol (2011) 0.85
EphA2-induced angiogenesis in ewing sarcoma cells works through bFGF production and is dependent on caveolin-1. PLoS One (2013) 0.85
Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination. Angiogenesis (2011) 0.85
Low-dosage inhibition of Dll4 signaling promotes wound healing by inducing functional neo-angiogenesis. PLoS One (2012) 0.84
EphB2 activation is required for ependymoma development as well as inhibits differentiation and promotes proliferation of the transformed cell. Sci Rep (2015) 0.84
DNA methylation profiles and biomarkers of oral squamous cell carcinoma. Epigenetics (2015) 0.83
Isolation and Characterization of a Monobody with a Fibronectin Domain III Scaffold That Specifically Binds EphA2. PLoS One (2015) 0.80
VEGF silencing inhibits human osteosarcoma angiogenesis and promotes cell apoptosis via PI3K/AKT signaling pathway. Int J Clin Exp Med (2015) 0.79
Anti-angiogenic alternatives to VEGF blockade. Clin Exp Metastasis (2015) 0.79
Eph/ephrin sytem: In the quest of novel anti-angiogenic therapies. Br J Pharmacol (2014) 0.78
Ephrin-Eph signaling as a potential therapeutic target for the treatment of myocardial infarction. Med Hypotheses (2013) 0.77
Discovery and characterization of a novel cyclic peptide that effectively inhibits ephrin binding to the EphA4 receptor and displays anti-angiogenesis activity. PLoS One (2013) 0.77
Ephrin-B3 supports glioblastoma growth by inhibiting apoptosis induced by the dependence receptor EphA4. Oncotarget (2017) 0.75
Dual microRNA Screens Reveal That the Immune-Responsive miR-181 Promotes Henipavirus Entry and Cell-Cell Fusion. PLoS Pathog (2016) 0.75
EphA4 may contribute to microvessel remodeling in the hippocampal CA1 and CA3 areas in a mouse model of temporal lobe epilepsy. Mol Med Rep (2016) 0.75
Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets. PLoS One (2016) 0.75
Mutational load and mutational patterns in relation to age in head and neck cancer. Oncotarget (2016) 0.75
EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins. Int J Med Sci (2016) 0.75
Engineering of monobody conjugates for human EphA2-specific optical imaging. PLoS One (2017) 0.75
Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review. J Adv Res (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Vascular-specific growth factors and blood vessel formation. Nature (2000) 14.42
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 13.76
Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell (1998) 10.61
Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol (1999) 7.66
Eph-ephrin bidirectional signaling in physiology and disease. Cell (2008) 7.12
Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol (2002) 6.92
Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev (1999) 4.75
Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling. Nat Neurosci (2004) 4.22
HuR binding to cytoplasmic mRNA is perturbed by heat shock. Proc Natl Acad Sci U S A (2000) 4.14
A multidimensional analysis of genes mutated in breast and colorectal cancers. Genome Res (2007) 4.09
Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Cell (2006) 3.51
Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol (1993) 3.15
A novel putative tyrosine kinase receptor encoded by the eph gene. Science (1987) 3.10
Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol (2000) 3.09
Bidirectional modulation of synaptic functions by Eph/ephrin signaling. Nat Neurosci (2008) 2.85
Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands. Nature (1996) 2.81
The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene (2000) 2.46
Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol (2001) 2.46
Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene (2000) 2.45
Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene (2002) 2.41
Tyrosine phosphorylation of transmembrane ligands for Eph receptors. Science (1997) 2.40
Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev (1998) 2.38
EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat Genet (2007) 2.33
Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol (2001) 2.25
The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev (2004) 2.23
Eph receptors and ephrins restrict cell intermingling and communication. Nature (1999) 2.23
The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res (2008) 2.21
Eph/ephrin signaling: networks. Genes Dev (2008) 2.13
The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest (2008) 2.11
Fibroblast growth factors are present in the extracellular matrix produced by endothelial cells in vitro: implications for a role of heparinase-like enzymes in the neovascular response. Biochem Biophys Res Commun (1987) 2.08
The receptor tyrosine kinase EphB2 regulates NMDA-dependent synaptic function. Neuron (2001) 2.02
Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci U S A (2004) 2.01
E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ (1999) 2.01
Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res (2007) 1.98
Modulation of EphA receptor function by coexpressed ephrinA ligands on retinal ganglion cell axons. Neuron (1999) 1.97
Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. Structure (2006) 1.97
Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res (2002) 1.96
Ephrin-A5 induces collapse of growth cones by activating Rho and Rho kinase. J Cell Biol (2000) 1.94
EphA4 (Sek1) receptor tyrosine kinase is required for the development of the corticospinal tract. Proc Natl Acad Sci U S A (1998) 1.91
Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res (2009) 1.90
The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration. Cell (2001) 1.88
Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol (2006) 1.83
EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J Cell Sci (2004) 1.82
Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J Biol Chem (2008) 1.80
The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev (2002) 1.80
Kinase-dependent and kinase-independent functions of EphA4 receptors in major axon tract formation in vivo. Neuron (2001) 1.75
An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem (2002) 1.74
Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res (2001) 1.73
Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res (2002) 1.70
Eph receptors and ephrins: effectors of morphogenesis. Development (1999) 1.69
Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J (2005) 1.61
Fighting cancer by attacking its blood supply. Sci Am (1996) 1.58
Paradoxes of the EphB4 receptor in cancer. Cancer Res (2007) 1.58
An Eph receptor regulates integrin activity through R-Ras. Proc Natl Acad Sci U S A (1999) 1.57
The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood (2005) 1.56
Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haemost (1997) 1.56
Eph receptor tyrosine kinases in angiogenesis: from development to disease. Angiogenesis (2004) 1.55
Kinase independent function of EphB receptors in retinal axon pathfinding to the optic disc from dorsal but not ventral retina. Development (2000) 1.55
Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name? Am J Pathol (1999) 1.54
Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res (2008) 1.52
Trophoblast functions, angiogenesis and remodeling of the maternal vasculature in the placenta. Mol Cell Endocrinol (2002) 1.50
The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology (1993) 1.50
Surface densities of ephrin-B1 determine EphB1-coupled activation of cell attachment through alphavbeta3 and alpha5beta1 integrins. EMBO J (1999) 1.49
EphB4 controls blood vascular morphogenesis during postnatal angiogenesis. EMBO J (2006) 1.48
Phosphorylation of tyrosine residues in the kinase domain and juxtamembrane region regulates the biological and catalytic activities of Eph receptors. Mol Cell Biol (2000) 1.47
Transcriptional profiling of human cord blood CD133+ and cultured bone marrow mesenchymal stem cells in response to hypoxia. Stem Cells (2006) 1.47
EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J Biol Chem (2005) 1.46
Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res (2004) 1.44
Eph-ephrin promiscuity is now crystal clear. Nat Neurosci (2004) 1.44
Artery and vein size is balanced by Notch and ephrin B2/EphB4 during angiogenesis. Development (2008) 1.43
Overexpression confers an oncogenic potential upon the eph gene. Oncogene (1990) 1.43
Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep (2008) 1.42
VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther (2006) 1.41
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Br J Cancer (2009) 1.41
Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene (2008) 1.41
The history of the angiogenic switch concept. Leukemia (2006) 1.40
Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3-expressing 293T and melanoma cells by CrkII and Rho-mediated signalling. J Cell Sci (2002) 1.38
EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. Blood (2009) 1.38
Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer (2009) 1.38
Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway. J Biol Chem (2002) 1.37
Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des (2004) 1.33
Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia (2004) 1.33
Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia (2003) 1.30
Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents. Cancer Res (2005) 1.28
Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells. J Cell Sci (2003) 1.28
Cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrin-B2 during mammary gland morphogenesis. J Cell Sci (1998) 1.27
Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer (2008) 1.27
Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett (2009) 1.26
EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res (2004) 1.25
Hypoxia-inducible transcription factor-2alpha in endothelial cells regulates tumor neovascularization through activation of ephrin A1. J Biol Chem (2008) 1.24
A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci U S A (1995) 1.21
Replacing two conserved tyrosines of the EphB2 receptor with glutamic acid prevents binding of SH2 domains without abrogating kinase activity and biological responses. Oncogene (2000) 1.21
Over-expression of EphB3 enhances cell-cell contacts and suppresses tumor growth in HT-29 human colon cancer cells. Carcinogenesis (2009) 1.19
The Eph family receptors and ligands. Pharmacol Ther (1998) 1.18
Eph-modulated cell morphology, adhesion and motility in carcinogenesis. IUBMB Life (2005) 1.18
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. Int J Cancer (2006) 1.18
Hypoxia up-regulates expression of Eph receptors and ephrins in mouse skin. FASEB J (2005) 1.18
Eph receptors and Ephrins in cancer: common themes and controversies. Cancer Res (2008) 1.17
Pulmonary blood flow increases in damaged regions directly after acid aspiration in rats. Anesthesiology (2013) 1.45
Localized proton magnetic resonance spectroscopy of lipids in adipose tissue at high spatial resolution in mice in vivo. J Lipid Res (2007) 1.26
Labeling of low-density lipoproteins using the 18F-labeled thiol-reactive reagent N-[6-(4-[18F]fluorobenzylidene)aminooxyhexyl]maleimide. Nucl Med Biol (2006) 1.20
Synthesis and application of [18F]FDG-maleimidehexyloxime ([18F]FDG-MHO): a [18F]FDG-based prosthetic group for the chemoselective 18F-labeling of peptides and proteins. Bioconjug Chem (2008) 1.15
Irradiation affects cellular properties and Eph receptor expression in human melanoma cells. Cell Adh Migr (2012) 0.93
L-type amino acid transporters LAT1 and LAT4 in cancer: uptake of 3-O-methyl-6-18F-fluoro-L-dopa in human adenocarcinoma and squamous cell carcinoma in vitro and in vivo. J Nucl Med (2007) 0.90
Systematic comparison of two novel, thiol-reactive prosthetic groups for 18F labeling of peptides and proteins with the acylation agent succinimidyl-4-[18F]fluorobenzoate ([18F]SFB). Amino Acids (2008) 0.89
Experimental hypoxia is a potent stimulus for radiotracer uptake in vitro: comparison of different tumor cells and primary endothelial cells. Cancer Lett (2007) 0.88
The pivotal role of scavenger receptor CD36 and phagocyte-derived oxidants in oxidized low density lipoprotein-induced adhesion to endothelial cells. Int J Biochem Cell Biol (2004) 0.88
In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. Diabetes (2002) 0.88
Synthesis and evaluation in vitro and in vivo of a 11C-labeled cyclooxygenase-2 (COX-2) inhibitor. Bioorg Med Chem (2008) 0.85
Effects of posture on regional pulmonary blood flow in rats as measured by PET. J Appl Physiol (1985) (2009) 0.84
Validation of different chemilumigenic substrates for detecting extracellular generation of reactive oxygen species by phagocytes and endothelial cells. Luminescence (2003) 0.84
S100A2 in cancerogenesis: a friend or a foe? Amino Acids (2010) 0.84
Cyclin-dependent kinase 4/6 (cdk4/6) inhibitors: perspectives in cancer therapy and imaging. Mini Rev Med Chem (2010) 0.83
Copper-mediated cross-linking of S100A4, but not of S100A2, results in proinflammatory effects in melanoma cells. Biochem Biophys Res Commun (2011) 0.83
Fluorine-18 radiolabeling and radiopharmacological characterization of a benzodioxolylpyrimidine-based radiotracer targeting the receptor tyrosine kinase EphB4. ChemMedChem (2012) 0.82
The protective effects of HDL and its constituents against neutrophil respiratory burst activation by hypochlorite-oxidized LDL. Mol Cell Biochem (2004) 0.82
Synthesis and radiopharmacological characterisation of a fluorine-18-labelled azadipeptide nitrile as a potential PET tracer for in vivo imaging of cysteine cathepsins. ChemMedChem (2013) 0.82
Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus. J Clin Endocrinol Metab (2003) 0.82
[Not Available]. J Oncol (2009) 0.81
Scavenger receptors are associated with cellular interactions of S100A12 in vitro and in vivo. Int J Biochem Cell Biol (2009) 0.81
Design, evaluation, and comparison of ghrelin receptor agonists and inverse agonists as suitable radiotracers for PET imaging. Bioconjug Chem (2012) 0.81
Radiosynthesis of a ¹⁸F-labeled 2,3-diarylsubstituted indole via McMurry coupling for functional characterization of cyclooxygenase-2 (COX-2) in vitro and in vivo. Bioorg Med Chem (2012) 0.81
Site-selective radiolabeling of peptides by (18)F-fluorobenzoylation with [(18F)]SFB in solution and on solid phase: a comparative study. Amino Acids (2012) 0.81
(18)F-Labeled phosphopeptide-cell-penetrating peptide dimers with enhanced cell uptake properties in human cancer cells. Nucl Med Biol (2012) 0.80
Specific targeting of hypoxic tumor tissue with nitroimidazole-peptide conjugates. ChemMedChem (2011) 0.80
Tissue transglutaminase: an emerging target for therapy and imaging. Bioorg Med Chem Lett (2013) 0.80
Synthesis and evaluation of 1,5-diaryl-substituted tetrazoles as novel selective cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med Chem Lett (2011) 0.80
Expression, purification and fluorine-18 radiolabeling of recombinant S100A4: a potential probe for molecular imaging of receptor for advanced glycation endproducts in vivo? Amino Acids (2010) 0.80
An efficient bioorthogonal strategy using CuAAC click chemistry for radiofluorinations of SNEW peptides and the role of copper depletion. ChemMedChem (2013) 0.80
Yttrium-86-labelled human serum albumin microspheres: relation of surface structure with in vivo stability. Nucl Med Biol (2007) 0.80
Radiolabeled COX-2 inhibitors for non-invasive visualization of COX-2 expression and activity--a critical update. Molecules (2013) 0.80
Radiosynthesis and radiopharmacological evaluation of cyclin-dependent kinase 4 (Cdk4) inhibitors. Eur J Med Chem (2009) 0.79
2-Carbaborane-3-phenyl-1H-indoles--synthesis via McMurry reaction and cyclooxygenase (COX) inhibition activity. ChemMedChem (2013) 0.79
Protein and non-protein biomarkers in melanoma: a critical update. Amino Acids (2012) 0.79
Influence of irradiation on metabolism and metastatic potential of B16-F10 melanoma cells. Int J Radiat Biol (2009) 0.79
In vivo fluorescence imaging and urinary monoamines as surrogate biomarkers of disease progression in a mouse model of pheochromocytoma. Endocrinology (2014) 0.78
Experimental hypoxia does not influence gene expression and protein synthesis of Eph receptors and ephrin ligands in human melanoma cells in vitro. Melanoma Res (2013) 0.78
Improved multimodality imaging using alginate molding in xenograft tumor models. J Magn Reson Imaging (2010) 0.78
Expression, purification and fluorine-18 radiolabeling of recombinant S100 proteins--potential probes for molecular imaging of receptor for advanced glycation endproducts (RAGE) in vivo. Protein Expr Purif (2007) 0.78
Synthesis of neurotensin(8-13)-phosphopeptide heterodimers via click chemistry. Bioorg Med Chem Lett (2010) 0.78
3-O-methyl-6-18F-fluoro-L-dopa, a new tumor imaging agent: investigation of transport mechanism in vitro. J Nucl Med (2004) 0.77
A novel tetrabranched neurotensin(8-13) cyclam derivative: synthesis, 64Cu-labeling and biological evaluation. J Inorg Biochem (2011) 0.77
Prediabetic and diabetic in vivo modification of circulating low-density lipoprotein attenuates its stimulatory effect on adrenal aldosterone and cortisol secretion. J Endocrinol (2008) 0.77
Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study. Atherosclerosis (2008) 0.76
Modulation of adrenal aldosterone release by oxidative modification of low-density lipoprotein. Am J Hypertens (2010) 0.76
Synthesis, characterization and biological evaluation of [188Re(N)(cys ∼)(PNP)]+/0 mixed-ligand complexes as prototypes for the development of 188Re(N)-based target-specific radiopharmaceuticals. Nucl Med Biol (2010) 0.76
Radiofluorination and first radiopharmacological characterization of a SWLAY peptide-based ligand targeting EphA2. J Labelled Comp Radiopharm (2014) 0.76
Visualization of cyclooxygenase-2 using a 2,3-diarylsubstituted indole-based inhibitor and confocal laser induced cryofluorescence microscopy at 20K in melanoma cells in vitro. Biochem Biophys Res Commun (2012) 0.76
Validation of (99m)Tc-labeled "4+1" fatty acids for myocardial metabolism and flow imaging: Part 1: myocardial extraction and biodistribution. Nucl Med Biol (2009) 0.76
S100 proteins in health and disease. Amino Acids (2010) 0.76
Fluorine-18 labeling of phosphopeptides: a potential approach for the evaluation of phosphopeptide metabolism in vivo. Biopolymers (2009) 0.76
Biodistribution and catabolism of 18F-labeled N-epsilon-fructoselysine as a model of Amadori products. Nucl Med Biol (2006) 0.76
Radiolabeled glucocorticoids as molecular probes for imaging brain glucocorticoid receptors by means of positron emission tomography (PET). Mini Rev Med Chem (2008) 0.75
Modified "4 + 1" mixed ligand technetium-labeled fatty acids for myocardial imaging: evaluation of myocardial uptake and biodistribution. Bioconjug Chem (2007) 0.75
Optimization of pentadentate bispidines as bifunctional chelators for 64Cu positron emission tomography (PET). Inorg Chem (2013) 0.75
Automated radiosynthesis of the thiol-reactive labeling agent N-[6-(4-[18F]fluorobenzylidene)aminooxyhexyl]maleimide ([18F]FBAM). Appl Radiat Isot (2011) 0.75
Synthesis and radiopharmacological characterization of [11C]AL-438 as a nonsteroidal ligand for imaging brain glucocorticoid receptors. Bioorg Med Chem Lett (2007) 0.75
Myocardial uptake and biodistribution of newly designed technetium-labelled fatty acid analogues. Nucl Med Commun (2007) 0.75
Phosphopeptides with improved cellular uptake properties as ligands for the polo-box domain of polo-like kinase 1. Bioorg Med Chem Lett (2011) 0.75
Radiosynthesis and radiopharmacological evaluation of [N-methyl-11C]Org 34850 as a glucocorticoid receptor (GR)-binding radiotracer. Appl Radiat Isot (2008) 0.75
Copper(II) chemistry of the functionalized macrocycle cyclam tetrapropionic acid. Dalton Trans (2012) 0.75
Corrigendum: Synthesis and Kinetic Characterisation of Water-Soluble Fluorogenic Acyl Donors for Transglutaminase 2. Chembiochem (2016) 0.75
Cyclopeptides containing the DEKS motif as conformationally restricted collagen telopeptide analogues: synthesis and conformational analysis. Org Biomol Chem (2015) 0.75
Synthesis and biological evaluation of a new type of 99mtechnetium-labeled Fatty Acid for myocardial metabolism imaging. Bioconjug Chem (2007) 0.75
Validation of (99m)Tc-labeled "4+1" fatty acids for myocardial metabolism and flow imaging: Part 2. Subcellular distribution. Nucl Med Biol (2009) 0.75
Bispidine dioxotetraaza macrocycles: a new class of bispidines for (64)Cu PET imaging. Inorg Chem (2014) 0.75
Reduction of arteriosclerotic nanoplaque formation and size by n-3 fatty acids in patients after valvular defect operation. Forsch Komplementmed (2009) 0.75
Lipid transfer protein activities in subjects with impaired glucose tolerance. Clin Chem Lab Med (2007) 0.75
Synthesis and cyclooxygenase inhibition of various (aryl-1,2,3-triazole-1-yl)-methanesulfonylphenyl derivatives. Bioorg Med Chem (2008) 0.75